Surgery – Instruments – Electrical application
Reexamination Certificate
2001-11-26
2004-10-12
Peffley, Michael (Department: 3739)
Surgery
Instruments
Electrical application
C128S898000, C607S133000
Reexamination Certificate
active
06802841
ABSTRACT:
FIELD OF THE INVENTION
In a general sense, the invention is directed to systems and methods for treating interior tissue regions of the body. More specifically, the invention is directed to systems and methods for treating dysfunction in body sphincters and adjoining tissue, e.g., in and around the lower esophageal sphincter and cardia of the stomach, or in and around the anal sphincter complex.
BACKGROUND OF THE INVENTION
Dysfunction of a sphincter in the body can lead to internal damage or disease, discomfort, or otherwise adversely affect patient quality of life. Gastroesophageal reflux disease (GERD), for example, is a common disorder caused most commonly by frequent transient relaxations of the lower esophageal sphincter (LES). If the lower esophageal sphincter fails to function properly, stomach contents, including acid, enzymes, and bile may flow backwards into the esophagus, causing heartburn or other disease symptoms, damage to the esophagus, and the development of precancerous lesions.
Fecal incontinence is the involuntary passage of solid or liquid stool through the anal canal. This is caused most commonly by previous damage to or aging of the external and/or internal sphincter muscles in the anal canal. Secondary causes are improper sensing and control of solid or liquid stool within the rectum.
The disease states of GERD and fecal incontinence have in common a defective sphincter barrier as a mechanism of the disease. The end result is the development of GERD and fecal incontinence symptoms due to inadequate barrier function. In both GERD and fecal incontinence, inadequate barrier function can be the result of either a mechanical defect in the sphincter, a low resting pressure in the sphincter, an overly compliant sphincter, abnormal afferent nerve impulses that trigger transient sphincter relaxations, or improper sensing of and control of lumenal contents.
SUMMARY OF THE INVENTION
The invention provides systems and methods that apply a selected treatment agent into contact with tissue at, or in, the region of a dysfunctional sphincter in order to affect improved sphincter barrier function and improve a disease state. The systems and methods may be used as either a primary treatment modality, or applied as a supplementary treatment before, during or after a primary intervention.
According to one aspect of the invention, the treatment agent includes at least one sub-type of a cytokine. Delivery of a cytokine to tissue evokes a desired tissue response, which can include, e.g., an initiation of a localized healing process including influx of white blood cells and fibroblasts, followed by deposition of collagen, and a subsequent reduction in tissue compliance and tightening. These effects will result in improved sphincter barrier function. The cytokine treatment agent may be applied to the surface of a tissue, or, alternatively, it may be injected below the surface of the tissue, including the submucosa, the sphincter itself, or the area surrounding the sphincter.
According to another aspect of the invention, the treatment agent may include a tissue bulking agent, which is injected into subsurface tissue, including the submucosa, the sphincter, or the area surrounding the sphincter. Presence of the bulking agent results in additional tissue compliance reduction and tightening to improve sphincter barrier function.
According to another aspect of the invention, the treatment agent includes at least one vanilloid compound. Presence of the vanilloid compound evokes a desired tissue response, which includes at least one of the following, e.g., the interruption of afferent nerve impulses which lead to impaired sphincter function or diminished pain impulses from the treated area. The vanilloid treatment agent may be applied to surface tissue, or, alternatively, it may be injected into subsurface tissue, including the submucosa, the sphincter, or the area surrounding the sphincter. In one embodiment, the systems and methods apply energy to the tissue region to form at least one lesion in conjunction with application of the treatment agent.
Features and advantages of the inventions are set forth in the following Description and Drawings, as well as in the appended claims.
REFERENCES:
patent: 1798902 (1931-03-01), Raney
patent: 3517128 (1970-06-01), Hines
patent: 3901241 (1975-08-01), Allen, Jr.
patent: 4011872 (1977-03-01), Komiya
patent: 4196724 (1980-04-01), Wirt et al.
patent: 4313958 (1982-02-01), LaHann
patent: 4411266 (1983-10-01), Cosman
patent: 4423812 (1984-01-01), Sato
patent: 4532924 (1985-08-01), Auth et al.
patent: 4565200 (1986-01-01), Cosman
patent: 4705041 (1987-11-01), Kim
patent: 4901737 (1990-02-01), Toone
patent: 4906203 (1990-03-01), Margrave et al.
patent: 4907589 (1990-03-01), Cosman
patent: 4939149 (1990-07-01), Blumberg
patent: 4943290 (1990-07-01), Rexroth et al.
patent: 4947842 (1990-08-01), Marchosky et al.
patent: 4955377 (1990-09-01), Lennox et al.
patent: 4966597 (1990-10-01), Cosman
patent: 4976711 (1990-12-01), Parins et al.
patent: 5019075 (1991-05-01), Spears et al.
patent: 5021450 (1991-06-01), Blumberg
patent: 5035696 (1991-07-01), Rydell
patent: 5046512 (1991-09-01), Murchie
patent: 5047028 (1991-09-01), Qian
patent: 5057107 (1991-10-01), Parins et al.
patent: 5078717 (1992-01-01), Parins et al.
patent: 5083565 (1992-01-01), Parins
patent: 5084044 (1992-01-01), Quint
patent: 5088979 (1992-02-01), Filipi et al.
patent: 5094233 (1992-03-01), Brennan
patent: 5100423 (1992-03-01), Fearnot
patent: 5106360 (1992-04-01), Ishiwara et al.
patent: 5122137 (1992-06-01), Lennox
patent: 5125928 (1992-06-01), Parins et al.
patent: 5156151 (1992-10-01), Imran
patent: 5190541 (1993-03-01), Abele et al.
patent: 5197963 (1993-03-01), Parins
patent: 5197964 (1993-03-01), Parins
patent: 5205287 (1993-04-01), Erbel et al.
patent: 5215103 (1993-06-01), Desai
patent: 5232444 (1993-08-01), Just et al.
patent: 5236413 (1993-08-01), Fiering
patent: 5242441 (1993-09-01), Avitall
patent: 5254126 (1993-10-01), Filipi et al.
patent: 5256138 (1993-10-01), Vurek et al.
patent: 5257451 (1993-11-01), Edwards et al.
patent: 5263493 (1993-11-01), Avitall
patent: 5275162 (1994-01-01), Edwards et al.
patent: 5275608 (1994-01-01), Forman et al.
patent: 5275610 (1994-01-01), Eberbach
patent: 5277201 (1994-01-01), Stern
patent: 5281216 (1994-01-01), Klicek
patent: 5281217 (1994-01-01), Edwards et al.
patent: 5281218 (1994-01-01), Imran
patent: 5290286 (1994-03-01), Parins
patent: 5292321 (1994-03-01), Lee
patent: 5293869 (1994-03-01), Edwards et al.
patent: 5309910 (1994-05-01), Edwards et al.
patent: 5313943 (1994-05-01), Houser et al.
patent: 5314466 (1994-05-01), Stern et al.
patent: 5316020 (1994-05-01), Truffer
patent: 5324284 (1994-06-01), Imran
patent: 5328467 (1994-07-01), Edwards et al.
patent: 5334196 (1994-08-01), Scott et al.
patent: 5336222 (1994-08-01), Durgin, Jr. et al.
patent: 5345936 (1994-09-01), Pomeranz et al.
patent: 5348554 (1994-09-01), Imran et al.
patent: 5363861 (1994-11-01), Edwards et al.
patent: 5365926 (1994-11-01), Desai
patent: 5365945 (1994-11-01), Halstrom
patent: 5366490 (1994-11-01), Edwards et al.
patent: 5368557 (1994-11-01), Nita et al.
patent: 5368592 (1994-11-01), Stern et al.
patent: 5370675 (1994-12-01), Edwards et al.
patent: 5370678 (1994-12-01), Edwards et al.
patent: 5383876 (1995-01-01), Nardella
patent: 5383917 (1995-01-01), Desai et al.
patent: 5385544 (1995-01-01), Edwards et al.
patent: 5397339 (1995-03-01), Desai
patent: 5398683 (1995-03-01), Edwards et al.
patent: 5401272 (1995-03-01), Perkins
patent: 5403311 (1995-04-01), Abele et al.
patent: 5409453 (1995-04-01), Lundquist et al.
patent: 5409483 (1995-04-01), Campbell et al.
patent: 5415657 (1995-05-01), Taymor-Luia
patent: 5421819 (1995-06-01), Edwards et al.
patent: 5423808 (1995-06-01), Edwards et al.
patent: 5423811 (1995-06-01), Ellman et al.
patent: 5423812 (1995-06-01), Ellman et al.
patent: 5431914 (1995-07-01), Adekunle et al.
patent: 5433739 (1995-07-01), Sluijter et al.
patent: 5435805 (1995-07-01), Edwards
patent: 5441499 (1995-08-01), Fritzsch
patent: 544347
Croft Rachel
Gaiser John W
Utley David S
Curon Medical, Inc.
Peffley Michael
Ryan Kromholz & Manion S.C.
LandOfFree
Systems and methods for applying a selected treatment agent... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Systems and methods for applying a selected treatment agent..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Systems and methods for applying a selected treatment agent... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3261663